Results 221 to 230 of about 73,540 (330)

Radiotherapy meets anticancer metallodrugs. [PDF]

Med Rev (2021)
Zhang S, Shen S, Li J, Fu Q, Guo Z, Liu Z.   +5 more
europepmc   +1 more source

Alkaline Phosphatases: A Potential Cause of Variability in Therapeutic Response to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion?

Movement Disorders, EarlyView.
Manon Auffret, Marc Vérin
wiley   +1 more source

Harnessing the Folding of Antitumor Peptides for Controlled Carrier‐Free Drug Delivery

Small, EarlyView.
A disulfide‐bridged stapled p53 α‐helix co‐assembled with doxorubicin into protease‐resistant nanocomplexes. Reductive intracellular conditions induced helix refolding and nanostructure disassembly, which enabled the coordinated release of the chemotherapeutic agent and anticancer peptide.
Jae Yun Lee, Moo Chang Park, Sung Chan Choi, Jieun Kim, Joo‐young Kim, Jiah Lee, Hyun Jin Kim, Kyobum Kim, Yongju Kim, Woo‐jin Jeong   +9 more
wiley   +1 more source

Heavy-Atom-Free Dual-Action Dual PACT/PDT action Pt(IV) Prodrug With BODIPY Dimer in Axial Position. [PDF]

ChemMedChem
Bykusov V, Isaeva Y, Akasov R, Egorova T, Mun V, Bunin D, Kuzmin V, Egorov A, Burtsev I, Grishin Y, Rodin I, Vokuev M, Beloglazkina E, Krasnovskaya O.   +13 more
europepmc   +1 more source

Redox‐responsive dual‐drug nanomedicine integrating cisplatin and trypsin for synergistic reversal of tumor chemoresistance

Smart Molecules, EarlyView.
This study presents a novel glutathione‐activatable prodrug nanomedicine (cRGD‐PEG‐PGlu‐NP (ssTrypsin & CDDP)) that co‐encapsulates cisplatin and a masked protease to combat cisplatin resistance. The dual‐drug system selectively targets resistant tumor cells, enhancing the efficacy of cisplatin while minimizing systemic toxicity.
Xiaolan Yin, Qi Wang, Ming Zhang, Cheng Zhang, Qixian Chen, Haidong Li, Yan Zhao, Yue Wang, Jingyun Wang, Liuwei Zhang, Hongyan Cui   +10 more
wiley   +1 more source

Engineering a conditionally active cetuximab prodrug via affibody-based paratope masking. [PDF]

J Biol Eng
Mestre Borras A, Mehari H, Bitzios A, Zelepukin I, Ud-Din M, Xu T, Li S, Orlova A, Tolmachev V, Ståhl S, Vorobyeva A, Löfblom J.   +11 more
europepmc   +1 more source

Stimuli‐responsive nanostructured hydrogen sulfide donors for enhanced cancer treatments

Smart Molecules, EarlyView.
Three typical kinds of stimuli‐responsive nanostructured hydrogen sulfide (H2S) donors are reviewed. The nanostructures ensure precise delivery of H2S to the lesion site and regulate the release behavior. The H2S‐based gas therapy has been used to synergize with other cancer treatment modalities, achieving enhanced efficacy while reducing side effects.
Yuxuan Lyu, Jiaxuan Zhu, Lei Lei, Qingyang Zhong, Zhao Li, Caihong Lei, Fan Rong, Yin Wang   +7 more
wiley   +1 more source

Enzymatic Laccase Nanoreactors Induce Apoptosis in MOLT-4-ALL Cells and Activate Prodrugs in a Synergetic Effect. [PDF]

Blood Lymphat Cancer
Medrano-Villagómez CA, Loredo-García E, Gasperin-Bulbarela J, Vazquez-Duhalt R.   +3 more
europepmc   +1 more source

A single‐molecule prodrug synergistically suppresses MYC‐amplified osteosarcoma through sequential nitric oxide release and photodynamic therapy

Smart Molecules, EarlyView.
A cascade‐responsive small‐molecule prodrug (DHU‐NO3) sequentially releases methylene blue (triggered by reactive oxygen species) and nitric oxide (controlled by 405 nm light), enabling precise spatiotemporal coordination of photodynamic therapy and NO gas therapy to effectively inhibit MYC‐amplified osteosarcoma growth.
Shuxin Peng, Jiangpeng Wu, Shasha Wang, Ying Gao, Xuran Guo, Mengpan Li, Youjin Wu, Yun Wang, Zhengdong Cai, Yingqi Hua, Peng Wei, Yinghua Gao, Tao Yi   +12 more
wiley   +1 more source

Design, synthesis and biological evaluation of a β-galactosidase-activated glycopeptide analogue of somatostatin. [PDF]

RSC Adv
O'Leary CJ, Corbezzolo S, Newton A, Benny A, Scanlan EM, Kolodziejczak K, Monaghan MG, McGouran JF.   +7 more
europepmc   +1 more source